Antitope Announces EpiScreen Collaboration with Zyngenia
Antitope Ltd. today announced a research collaboration with Zyngenia, Inc. ("Zyngenia") whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of a series of therapeutic ZybodyTM molecules being developed by Zyngenia to address multiple biological targets with single agents.
"We are very pleased to be working with Zyngenia whom we recognize as being at the forefront in the development of novel antibody-like therapeutics by applying their ZybodyTM technology," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "We look forward to assisting Zyngenia in selecting ZybodiesTM with a low potential for immunogenicity."
“As we move our research programs towards clinical trials, we are pleased to work with Antitope. The use of Antitope’s platform to identify potential immunogenicity issues quickly should allow us to further de-risk ZybodyTM programs at an early stage in their drug development life cycle,” said Peter Kiener, D.Phil., Chief Executive Officer and co-founder of Zyngenia.
About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit
http://www.antitope.co.uk or contact:
Dr. Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
About Zyngenia
Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybody™). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies. www.zyngenia.com
About ZybodiesTM
Zybodies™ are designed to incorporate the traditional attributes of monoclonal antibodies (mAbs) such as stability, ease of production, half-life, and effector function, into a single antibody-like protein that is able to interact with multiple targets. This multi-specificity of Zybodies™ enables them to recognize up to five different antigens concomitantly (termed “single protein-combination therapy”) and it is this feature that distinguishes them from conventional monoclonal antibodies that recognize a single target.